Over the past decade, there have been undoubtedly growing armamentaria in the treatment of NSCLC, focusing on personalized and targeted approach.doi:10.4236/alc.2012.11001James Chung-Man Ho肺癌(英文)James Chung-Man Ho. (2012) Treatment of non-small cell lung cancer in the era of targeted ...
neoadjuvant chemo in the treatment of nsclc新辅助化疗在非小细胞肺癌治疗中应用.pdf,Neoadjuvant chemotherapy in the treatment of nonsmall-cell lung cancer Rebecca De Pauw and Jan P. van Meerbeeck Purpose of review Introduction and background To review the
过去的二十年间,肺叶切除及系统性淋巴结清扫已成为早期非小细胞肺癌(non-small cell lung cancer,NSCLC)的标准手术方式[1]。然而,由于肺癌筛查工作的广泛深入,肺部结节数量显著增加,尤其是直径2 cm以内的早期肺癌所占比例正在逐步提高。在这种情况下,是否仍需对这...
LUMAKRAS®is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC): that has spread to other parts of the body or cannot be removed by surgery,and whose tumor has an abnormal KRAS G12C gene,and who have received at least one prior treatment for their canc...
1.. Non-small cell lung cancer Many things have changed in the history of non-small cell lung cancer (NSCLC) over the past 50 years. Much of it has been summarized in the special issue of the European Journal of Cancer commemorating the 40-year anniversary of the EORTC,1 and therefore ...
Stage IV non–small-cell lung cancer (NSCLC) patients with oligometastases (< 5 metastatic lesions) may experience long-term survival when all macroscopic tumor sites are treated radically, but no prospective data on NSCLCs with synchronous oligometastases are available. Methods A prospective single...
SUMMARYOver the last fifteen years, significant advances have been made in understanding the mechanisms and pathways that drive tumor growth in patients with non-small cell lung cancer (NSCLC). Molecular testing has become routine, and results directly impact clinical decision-making. The discovery ...
What Is Non-Small-Cell Lung Cancer (NSCLC)? Most people who havelung cancerhave NSCLC. Although it's serious, treatment can sometimes stop it from getting worse. There are things you can do to help you feel better, too. People who smoke or who breathe a lot of smoke are most likely ...
Blumenschein GR., Jr Developmental antiangiogenic agents for the treatment of non-small cell lung cancer (NSCLC) . Invest New Drugs (2012) 30 ( 4 ):1802–1110.1007/s10637-011-9750-1 [ Cross Ref ]George R., Blumenschein. (2011) Developmental antiangiogenic agents for the treatment of Non...
Docetaxel, a semisynthetic taxane, was the first agent to show efficacy in the second-line treatment of non-small cell lung cancer (NSCLC), and has since become a mainstay of NSCLC therapy. We review its mode of action, pharmacology, toxicity and efficacy and describe both its established ro...